Vytrus Biotech S.A. (VYT) - Total Liabilities

Latest as of December 2025: €4.35 Million EUR ≈ $5.09 Million USD

Based on the latest financial reports, Vytrus Biotech S.A. (VYT) has total liabilities worth €4.35 Million EUR (≈ $5.09 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Vytrus Biotech S.A. - Total Liabilities Trend (2020–2025)

This chart illustrates how Vytrus Biotech S.A.'s total liabilities have evolved over time, based on quarterly financial data. See VYT net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Vytrus Biotech S.A. Competitors by Total Liabilities

The table below lists competitors of Vytrus Biotech S.A. ranked by their total liabilities.

Company Country Total Liabilities
Bassett Furniture Industries
NASDAQ:BSET
USA $158.71 Million
YESASIA HOLDINGS LTD
F:4CM
Germany €83.70 Million
Nynomic AG
F:M7U
Germany €32.87 Million
AYER Holdings Bhd
KLSE:2305
Malaysia RM104.27 Million
Centratama Telekomunikasi Ind
JK:CENT
Indonesia Rp24.58 Trillion
Genesis Land Development Corp.
TO:GDC
Canada CA$297.77 Million
Vestland Berhad
KLSE:0273
Malaysia RM693.96 Million
SKM Egg Products Export (India) Limited
NSE:SKMEGGPROD
India Rs2.43 Billion

Liability Composition Analysis (2020–2025)

This chart breaks down Vytrus Biotech S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Vytrus Biotech S.A. stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.03 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.42 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.30 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Vytrus Biotech S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Vytrus Biotech S.A. (2020–2025)

The table below shows the annual total liabilities of Vytrus Biotech S.A. from 2020 to 2025.

Year Total Liabilities Change
2025-12-31 €4.35 Million
≈ $5.09 Million
+13.44%
2024-12-31 €3.84 Million
≈ $4.49 Million
-4.57%
2023-12-31 €4.02 Million
≈ $4.70 Million
+23.76%
2022-12-31 €3.25 Million
≈ $3.80 Million
+10.85%
2021-12-31 €2.93 Million
≈ $3.43 Million
+12.83%
2020-12-31 €2.60 Million
≈ $3.04 Million
--

About Vytrus Biotech S.A.

MC:VYT Spain Biotechnology
Market Cap
$159.93 Million
€136.80 Million EUR
Market Cap Rank
#18110 Global
#117 in Spain
Share Price
€18.20
Change (1 day)
+1.11%
52-Week Range
€3.98 - €19.80
All Time High
€19.80
About

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Lon… Read more